OSR Holdings, Inc. (OSRH)

NCM – Real Time Price. Currency in USD

0.64

+0.07 (13.09%)

At close: May 12, 2026, 4:00 PM EDT

0.63

-0.02 (-2.66%)

After-hours: May 12, 2026, 7:59 PM EDT

05.05.2026

Emerging Growth Research Issues Flash Report on OSR Holdings, Reaffirms Buy-Emerging Rating and $10.00 Price Target

NEW YORK, NY / ACCESS Newswire / May 5, 2026 / Emerging Growth Research today issued a flash report on OSR Holdings, Inc. (Nasdaq:OSRH), reaffirming its Buy-Emerging rating and 12-month price target of $10.00. The flash report highlights OSRH's execution of an $815 million definitive exclusive license agreement with BCM Europe AG (BCME) for the global development, commercialization, and out-licensing of VXM01 - a Phase-2b/3 ready oral immunotherapy for glioblastoma multiforme (GBM) and pancreatic cancer.

30.04.2026

OSR Holdings to Present VXM01 Licensing Agreement at Emerging Growth Conference May 7, 2026

OSR Holdings to Present VXM01 Licensing Agreement at Emerging Growth Conference May 7, 2026 BELLEVUE, WA / ACCESS Newswire / April 30, 2026 / OSR Holdings, Inc. (NASDAQ:OSRH), a global healthcare holding company advancing biomedical innovations to improve health and wellness worldwide, today announced that management will present at the upcoming Emerging Growth Conference. The presentation will provide investors and analysts with an overview of the Company's landmark VXM01 global licensing agreement and its implications for OSRH shareholders.

29.04.2026

OSR Holdings Executes Definitive $815 Million Global License Agreement for VXM01 with BCM Europe

Largest shareholder pledges entire equity stake as collateral for milestone obligations, reinforcing alignment with public shareholders BELLEVUE, WA / ACCESS Newswire / April 29, 2026 / OSR Holdings, Inc. (NASDAQ:OSRH) today announced that it has entered into a definitive global exclusive license agreement (the "Agreement") with BCM Europe AG ("BCME") for the development, commercialization, and potential sublicensing of VXM01, its Phase 3-ready oral immunotherapy targeting VEGFR-2. The Agreement builds on the previously disclosed binding term sheet and establishes a structured framework to advance VXM01, with alignment across OSRH, its largest shareholder BCME, and public shareholders.

09.04.2026

OSR Holdings Eliminates $2.02 Million Warrant Overhang with Premium-Priced Convertible Note

BELLEVUE, WA / ACCESS Newswire / April 9, 2026 / OSR Holdings, Inc. (NASDAQ:OSRH) ("OSR Holdings" or the "Company") today announced a strategic transaction for capital structure optimization with White Lion GBM Innovation Fund ("White Lion"), centered on the retirement of approximately $2.02 million of warrant overhang. Elimination of $2.02 Million Warrant Overhang As part of the transaction, OSR Holdings has retired approximately $2.02 million of outstanding warrants by consolidating them into a newly issued convertible promissory note.

30.03.2026

OSR Holdings to Update Investors at the Emerging Growth Conference on April 1, 2026

BELLEVUE, WA / ACCESS Newswire / March 30, 2026 / OSR Holdings, Inc. (NASDAQ:OSRH), a global healthcare holding company advancing biomedical innovations to improve health and wellness worldwide, today announced that management will present at the upcoming Emerging Growth Conference. The presentation will provide investors and analysts with an updated overview of the Company's recent strategic milestones - including its VXM01 oncology asset and Woori IO's noninvasive glucose monitoring platform - and its outlook for continued growth.

27.03.2026

Emerging Growth Research Issues Flash Report on OSR Holdings, Inc., Reaffirms Buy-Emerging Rating and $10.00 Price Target

NEW YORK CITY, NY / ACCESS Newswire / March 27, 2026 / Emerging Growth Research today issued a flash report on OSR Holdings, Inc. (Nasdaq:OSRH), reaffirming its Buy-Emerging rating and 12-month price target of $10.00. The flash report highlights recent developments related to the Company's non-invasive glucose monitoring technology (Woori IO), including increasing global interest in potential licensing and distribution opportunities.

23.03.2026

OSR Holdings Updates $815 Million VXM01 Licensing Deal Structure to Capture Value at Parent Level

BELLEVUE, WA / ACCESS Newswire / March 23, 2026 / OSR Holdings, Inc. (NASDAQ:OSRH) today announced an updated structure of its previously disclosed binding term sheet dated January 13, 2026 with BCM Europe AG for the global licensing of its lead oncology asset VXM01. The revised structure is designed to improve capital efficiency and shift economic benefits directly to the parent company, OSR Holdings and its shareholders.

Videos

No Data

There is no data to display

Press releases

05.05.2026

Emerging Growth Research Issues Flash Report on OSR Holdings, Reaffirms Buy-Emerging Rating and $10.00 Price Target

29.04.2026

OSR Holdings Executes Definitive $815 Million Global License Agreement for VXM01 with BCM Europe

09.04.2026

OSR Holdings Eliminates $2.02 Million Warrant Overhang with Premium-Priced Convertible Note

30.03.2026

OSR Holdings, Inc. (OSRH)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

OSR Holdings, Inc. (OSRH)

Emerging Growth Research Issues Flash Report on OSR Holdings, Reaffirms Buy-Emerging Rating and $10.00 Price Target

OSR Holdings to Present VXM01 Licensing Agreement at Emerging Growth Conference May 7, 2026

OSR Holdings Executes Definitive $815 Million Global License Agreement for VXM01 with BCM Europe

OSR Holdings Eliminates $2.02 Million Warrant Overhang with Premium-Priced Convertible Note

OSR Holdings to Update Investors at the Emerging Growth Conference on April 1, 2026

Emerging Growth Research Issues Flash Report on OSR Holdings, Inc., Reaffirms Buy-Emerging Rating and $10.00 Price Target

OSR Holdings Updates $815 Million VXM01 Licensing Deal Structure to Capture Value at Parent Level

Videos

No Data

Press releases

Emerging Growth Research Issues Flash Report on OSR Holdings, Reaffirms Buy-Emerging Rating and $10.00 Price Target

OSR Holdings Executes Definitive $815 Million Global License Agreement for VXM01 with BCM Europe

OSR Holdings Eliminates $2.02 Million Warrant Overhang with Premium-Priced Convertible Note

OSR Holdings to Update Investors at the Emerging Growth Conference on April 1, 2026

Emerging Growth Research Issues Flash Report on OSR Holdings, Reaffirms Buy-Emerging Rating and $10.00 Price Target

OSR Holdings to Present VXM01 Licensing Agreement at Emerging Growth Conference May 7, 2026

OSR Holdings Executes Definitive $815 Million Global License Agreement for VXM01 with BCM Europe

OSR Holdings Eliminates $2.02 Million Warrant Overhang with Premium-Priced Convertible Note

OSR Holdings to Update Investors at the Emerging Growth Conference on April 1, 2026

Emerging Growth Research Issues Flash Report on OSR Holdings, Inc., Reaffirms Buy-Emerging Rating and $10.00 Price Target

OSR Holdings Updates $815 Million VXM01 Licensing Deal Structure to Capture Value at Parent Level

Videos

No Data

Press releases

Emerging Growth Research Issues Flash Report on OSR Holdings, Reaffirms Buy-Emerging Rating and $10.00 Price Target

OSR Holdings Executes Definitive $815 Million Global License Agreement for VXM01 with BCM Europe

OSR Holdings Eliminates $2.02 Million Warrant Overhang with Premium-Priced Convertible Note

OSR Holdings to Update Investors at the Emerging Growth Conference on April 1, 2026

Search stocks

OSR Holdings, Inc. (OSRH)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

OSR Holdings, Inc. (OSRH)

Emerging Growth Research Issues Flash Report on OSR Holdings, Reaffirms Buy-Emerging Rating and $10.00 Price Target

OSR Holdings to Present VXM01 Licensing Agreement at Emerging Growth Conference May 7, 2026

OSR Holdings Executes Definitive $815 Million Global License Agreement for VXM01 with BCM Europe

OSR Holdings Eliminates $2.02 Million Warrant Overhang with Premium-Priced Convertible Note

OSR Holdings to Update Investors at the Emerging Growth Conference on April 1, 2026

Emerging Growth Research Issues Flash Report on OSR Holdings, Inc., Reaffirms Buy-Emerging Rating and $10.00 Price Target

OSR Holdings Updates $815 Million VXM01 Licensing Deal Structure to Capture Value at Parent Level

Videos

No Data

Press releases

Emerging Growth Research Issues Flash Report on OSR Holdings, Reaffirms Buy-Emerging Rating and $10.00 Price Target

OSR Holdings Executes Definitive $815 Million Global License Agreement for VXM01 with BCM Europe

OSR Holdings Eliminates $2.02 Million Warrant Overhang with Premium-Priced Convertible Note

OSR Holdings to Update Investors at the Emerging Growth Conference on April 1, 2026

Emerging Growth Research Issues Flash Report on OSR Holdings, Reaffirms Buy-Emerging Rating and $10.00 Price Target

OSR Holdings to Present VXM01 Licensing Agreement at Emerging Growth Conference May 7, 2026

OSR Holdings Executes Definitive $815 Million Global License Agreement for VXM01 with BCM Europe

OSR Holdings Eliminates $2.02 Million Warrant Overhang with Premium-Priced Convertible Note

OSR Holdings to Update Investors at the Emerging Growth Conference on April 1, 2026

Emerging Growth Research Issues Flash Report on OSR Holdings, Inc., Reaffirms Buy-Emerging Rating and $10.00 Price Target

OSR Holdings Updates $815 Million VXM01 Licensing Deal Structure to Capture Value at Parent Level

Videos

No Data

Press releases

Emerging Growth Research Issues Flash Report on OSR Holdings, Reaffirms Buy-Emerging Rating and $10.00 Price Target

OSR Holdings Executes Definitive $815 Million Global License Agreement for VXM01 with BCM Europe

OSR Holdings Eliminates $2.02 Million Warrant Overhang with Premium-Priced Convertible Note

OSR Holdings to Update Investors at the Emerging Growth Conference on April 1, 2026